Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Pfizer : Positive Preliminary Phase 2 Results for 20-Valent Vaccine Candidate in Infants

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2019 | 08:57am EDT

By Colin Kellaher

Pfizer Inc. (PFE) on Monday reported positive preliminary results from a phase 2 proof-of-concept study of its 20-valent pneumococcal conjugate vaccine candidate in infants.

The New York drug maker said the initial three doses in the four-dose study showed preliminary evidence that the vaccine candidate in infants has an overall safety profile similar to Pfizer's Prevnar 13 vaccine.

Pfizer said the findings should support the program's advancement to phase 3 studies, adding that it will discuss phase 3 plans with regulators once data with the fourth dose are available.

Pfizer said the study is assessing the safety and immunogenicity of the 20vPnC candidate for the prevention of invasive disease and otitis media caused by Streptococcus pneumoniae serotypes contained in the vaccine in healthy infants.

The 20vPnC candidate includes the 13 serotypes contained in Prevnar 13, plus seven additional Streptococcus pneumoniae serotypes that represent prevalent circulating global disease strains, the company said.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
PFIZER -0.99% 36.91 Delayed Quote.-15.44%
PFIZER LTD 1.51% 3293.2 End-of-day quote.16.66%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
09/13Biopharmaceutical Company Imara Inc. Files Confidentially for IPO
DJ
09/12PFIZER : Description Initial Statement of Beneficial Ownership
PU
09/12PFIZER : SpringWorks Therapeutics IPO Prices at High End of Range
DJ
09/12PFIZER : Catalia Health and Pfizer collaborate to better understand patient jour..
PU
09/12GLAXOSMITHKLINE : ViiV Healthcare - Stigma and mental health challenges remain b..
AQ
09/12SpringWorks Raises IPO to 9 Million Shares at $16-$18 Each
DJ
09/10PFIZER : Description Filing of certain prospectuses and communications in connec..
PU
09/10PFIZER : Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 ..
AQ
09/09PFIZER : Positive Preliminary Phase 2 Results for 20-Valent Vaccine Candidate in..
DJ
09/09PFIZER : Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 ..
BU
More news
Financials (USD)
Sales 2019 51 636 M
EBIT 2019 18 934 M
Net income 2019 11 493 M
Debt 2019 30 786 M
Yield 2019 3,88%
P/E ratio 2019 16,0x
P/E ratio 2020 15,6x
EV / Sales2019 4,55x
EV / Sales2020 4,83x
Capitalization 204 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 43,38  $
Last Close Price 36,91  $
Spread / Highest target 49,0%
Spread / Average Target 17,5%
Spread / Lowest Target -18,7%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-15.44%204 151
JOHNSON & JOHNSON1.07%345 150
ROCHE HOLDING LTD.10.52%236 116
MERCK AND COMPANY8.11%211 513
NOVARTIS18.45%200 777
NOVO NORDISK AS14.89%118 168